Chemotherapy agents and timing of chemotherapy in prostate cancer management
Donohue K, Petrylak D. Chemotherapy agents and timing of chemotherapy in prostate cancer management. Current Prostate Reports 2005, 3: 58-61. DOI: 10.1007/s11918-005-0017-1.Peer-Reviewed Original ResearchHormone-refractory prostate cancerSurvival benefitProstate cancerMetastatic hormone-refractory prostate cancerProstate-specific antigen levelTiming of chemotherapyPhase 2 trialProstate cancer managementMedian survivalPalliative benefitSurvival improvementAntigen levelsClinical trialsChemotherapy agentsCancer managementSingle agentChemotherapeutic agentsDocetaxelTrialsPhase 3Preliminary dataChemotherapyEstramustinePatientsCancer